Ryan Sabour
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ryan Sabour has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Argyrios Ziogas
2 shared publications- Gelareh Sadigh
University of California Irvine School of Medicine
2 shared publications Wen-Pin Chen
2 shared publications- Ali Sasani
Department of Radiological Sciences, University of California, Irvine, Orange, CA 92868-3201 (D.S., M.P., S.A., A.S., D.F., R.H.).
1 shared publication - Brandon Liu1 shared publication
- Chang Shu
University of California, San Francisco, School of Medicine - 505 Parnassus Ave, San Francisco, CA 94143, USA
1 shared publication
Latest Publications
- Open Access
- 13 October 2026
- Published by Elsevier in Journal of the American College of Radiology
Natural Language Processing for Automated Lung Cancer Screening Eligibility Classification from Electronic Health Record
- 13 October 2026
- Published by Elsevier in Journal of the American College of Radiology
Open AccessNatural Language Processing for Automated Lung Cancer Screening Eligibility Classification from Electronic Health Record
- Open Access
- 1 December 2025
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 22 (12) , 1500-1509
Reliability of Electronic Medical Record to Assess Patient’s Eligibility for Lung Cancer Screening: Analysis of Two Pilot Trials
- 1 December 2025
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 22 (12) , 1500-1509
Open AccessReliability of Electronic Medical Record to Assess Patient’s Eligibility for Lung Cancer Screening: Analysis of Two Pilot Trials
- Open Access
- 7 January 2025
- Published by Elsevier in Radiology Case Reports
- Vol. 20 (3) , 1726-1735
Role of imaging in the diagnosis and management of mixed epithelial and stromal tumors of the kidney: Case series and comprehensive review
- 7 January 2025
- Published by Elsevier in Radiology Case Reports
- Vol. 20 (3) , 1726-1735
Open AccessRole of imaging in the diagnosis and management of mixed epithelial and stromal tumors of the kidney: Case series and comprehensive review
- Open Access
- 1 January 2025
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 13
Dasatinib-induced renal (or chronic) thrombotic microangiopathy in a patient with chronic myeloid leukemia: A case report
Thrombotic microangiopathy encompasses microvascular thrombosis, hemolytic anemia, thrombocytopenia, and end-organ damage. Secondary thrombotic microangiopathy can result from malignancies, autoimmune diseases, or treatments such as tyrosine kinase inhibitors. Dasatinib, a tyrosine kinase inhibitor used in managing chronic myeloid leukemia, has been linked to thrombotic microangiopathy. This report describes a 66-year-old female with chronic myeloid leukemia treated with dasatinib who developed renal-limited thrombotic microangiopathy. Progressive renal dysfunction found in the context of chronic kidney disease prompted extensive lab evaluation and evaluation, with a renal biopsy confirming thrombotic microangiopathy attributed to dasatinib-induced nephrotoxicity. Discontinuation of dasatinib led to a slight improvement in renal function; however, progressive decline necessitated dialysis. This case underscores the diagnostic and therapeutic challenges of dasatinib-induced thrombotic microangiopathy, emphasizing renal biopsy in diagnosis and monitoring. Individualized treatment strategies and further research should be conducted to optimize future outcomes.
- 1 January 2025
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 13
Open AccessDasatinib-induced renal (or chronic) thrombotic microangiopathy in a patient with chronic myeloid leukemia: A case report
Thrombotic microangiopathy encompasses microvascular thrombosis, hemolytic anemia, thrombocytopenia, and end-organ damage. Secondary thrombotic microangiopathy can result from malignancies, autoimmune diseases, or treatments such as tyrosine kinase inhibitors. Dasatinib, a tyrosine kinase inhibitor used in managing chronic myeloid leukemia, has been linked to thrombotic microangiopathy. This report describes a 66-year-old female with chronic myeloid leukemia treated with dasatinib who developed renal-limited thrombotic microangiopathy. Progressive renal dysfunction found in the context of chronic kidney disease prompted extensive lab evaluation and evaluation, with a renal biopsy confirming thrombotic microangiopathy attributed to dasatinib-induced nephrotoxicity. Discontinuation of dasatinib led to a slight improvement in renal function; however, progressive decline necessitated dialysis. This case underscores the diagnostic and therapeutic challenges of dasatinib-induced thrombotic microangiopathy, emphasizing renal biopsy in diagnosis and monitoring. Individualized treatment strategies and further research should be conducted to optimize future outcomes.